A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C, Corbin JM, Thibivilliers S, Webb ZD, Zhao YD, Koster J, Fung KM, Asch AS, Wren JD, Ruiz-EchevarrÃa MJ. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer. BMC Cancer. 2019 May 06; 19(1):423.
-
Adult
-
Adult
-
Aged
-
Aged
-
Aged, 80 and over
-
Aged, 80 and over
-
Biomarkers, Tumor
-
Biomarkers, Tumor
-
Cell Cycle
-
Cell Cycle
-
Cell Line, Tumor
-
Cell Line, Tumor
-
Datasets as Topic
-
Datasets as Topic
-
Disease Progression
-
Disease Progression
-
Disease-Free Survival
-
Disease-Free Survival
-
Gene Expression Profiling
-
Gene Expression Profiling
-
Gene Expression Regulation, Neoplastic
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Humans
-
Male
-
Male
-
Membrane Proteins
-
Membrane Proteins
-
Middle Aged
-
Middle Aged
-
Neoplasm Proteins
-
Neoplasm Proteins
-
Neoplasm Recurrence, Local
-
Neoplasm Recurrence, Local
-
Predictive Value of Tests
-
Predictive Value of Tests
-
Prognosis
-
Prognosis
-
Prostate
-
Prostate
-
Prostatectomy
-
Prostatectomy
-
Prostatic Neoplasms
-
Prostatic Neoplasms
-
Retrospective Studies
-
Retrospective Studies
-
RNA, Messenger
-
RNA, Messenger
-
Transcriptome
-
Transcriptome